Actively Recruiting
DETECTion of the Prevalence of Silent Atherosclerosis Across Adult Life
Led by Rigshospitalet, Denmark · Updated on 2024-11-18
16000
Participants Needed
5
Research Sites
399 weeks
Total Duration
On this page
Sponsors
R
Rigshospitalet, Denmark
Lead Sponsor
T
The Novo Nordic Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Atherosclerosis is preventable, yet it continues to significantly contribute to global morbidity and mortality. Atherosclerosis may occur early in life and may present in all vascular territories. The DETECT study's main aim is to determine the prevalence of asymptomatic atherosclerosis (silent) in an adult population of a wide age range of European ancestry through vascular ultrasound (VUS) of peripheral arteries (carotid and femoral territories), as well as establishing the relationship between atherosclerosis in peripheral arteries, coronary arteries, and other vascular territories assessed by computed tomography angiography (CTA). The DETECT study also aims to identify risk factors for development of subclinical atherosclerosis that can hopefully improve the detection of the risk for development of atherosclerotic cardiovascular disease (ASCVD) with far higher precision than currently. In future research, the findings in this descriptive study may eventually be used as part of an age-adapted imaging-based screening for subclinical atherosclerosis. The investigators hypothesize that a precision medicine-based approach to identify candidates likely to benefit from primary prevention against atherosclerosis, may improve medical decision making, by combining traditional risk factors, including lifestyle and psychological factors, phenotypic findings and findings on vascular imaging, and patterns of circulating biomarkers to identify risk of atherosclerosis especially in young individuals and at earlier disease stages (the ultimate population target of REACT project, phase II), maximizing the potential for prevention long before overt disease occurs. An essential aspect of this approach is to pinpoint the specific risk factors in each individual that primarily drive atherosclerosis throughout their life and could serve as therapeutic targets. Thus, the overall purpose of this study is to establish the necessary knowledge, including extensive characterisation of atherosclerosis across life and thus add to the rational foundation for future development of a far more efficient and precise prophylaxis against ASCVD as compared with the presently applied methods.
CONDITIONS
Official Title
DETECTion of the Prevalence of Silent Atherosclerosis Across Adult Life
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 70 years with a balanced sex ratio in each 10-year age group
- No prior diagnosis of atherosclerotic cardiovascular disease (ASCVD)
- Recruitment from sites in Denmark and Spain
- Ability to read and understand Danish, English, Spanish, or Arabic
You will not qualify if you...
- Severe kidney disease with eGFR less than 30 ml
- Allergy to contrast dye used in CT scans
- Pregnancy
- Other conditions that prevent safe CT scanning with contrast
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
2
Righospitalet - Glostrup Hospital
Glostrup Municipality, Denmark
Actively Recruiting
3
Herlev Hospital
Herlev, Denmark, 2730
Not Yet Recruiting
4
Regionshospitalet Gødstrup
Herning, Denmark, 7400
Actively Recruiting
5
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
Madrid, Spain, E-28029
Not Yet Recruiting
Research Team
H
Henning Bundgaard, Professor
CONTACT
A
Anna Ringgaard, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here